Mural Oncology PLC (NASDAQ:MURA) Receives $12.00 Consensus PT from Brokerages

Mural Oncology PLC (NASDAQ:MURA) has been given an average recommendation of “Hold” by the five research firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $12.00.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Mural Oncology in a report on Monday, December 8th.

Hedge Funds Weigh In On Mural Oncology

A number of large investors have recently modified their holdings of MURA. Soleus Capital Management L.P. bought a new stake in Mural Oncology during the 2nd quarter worth approximately $3,270,000. Orbimed Advisors LLC purchased a new position in shares of Mural Oncology during the 2nd quarter valued at $1,454,000. LMR Partners LLP bought a new position in shares of Mural Oncology in the second quarter worth $1,276,000. Diametric Capital LP purchased a new stake in shares of Mural Oncology in the second quarter worth $864,000. Finally, Deltec Asset Management LLC purchased a new stake in shares of Mural Oncology in the third quarter worth $371,000. 80.21% of the stock is currently owned by institutional investors.

Mural Oncology Stock Performance

MURA opened at $2.04 on Friday. Mural Oncology has a 12 month low of $0.95 and a 12 month high of $4.74. The company has a market cap of $35.38 million, a PE ratio of -0.29 and a beta of 2.93. The company has a 50 day moving average of $2.05 and a 200 day moving average of $2.11.

Mural Oncology (NASDAQ:MURA) last posted its earnings results on Thursday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.38. Research analysts forecast that Mural Oncology will post -7.54 earnings per share for the current fiscal year.

Mural Oncology Company Profile

Mural Oncology, Inc (NASDAQ: MURA) is a clinical-stage biotechnology company focused on discovering and developing innovative therapies for cancer. The company’s research emphasizes targeting the tumor microenvironment and stromal resistance mechanisms to enhance the efficacy of existing and novel oncology agents.

Mural’s pipeline features small-molecule programs designed to inhibit signaling pathways involved in tumor growth and extracellular matrix remodeling. Its lead candidates are advancing through early-phase clinical trials in various solid tumors, leveraging translational biology tools such as patient-derived models and molecular profiling to guide drug discovery and patient selection.

Headquartered in San Mateo, California, Mural Oncology conducts research and development in the United States and collaborates with academic institutions and industry partners to support global clinical development.